Compare LNSR & KALA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LNSR | KALA |
|---|---|---|
| Founded | 2004 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Electronics | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 146.7M | 172.0M |
| IPO Year | 2005 | 2017 |
| Metric | LNSR | KALA |
|---|---|---|
| Price | $5.69 | $3.08 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 3 |
| Target Price | $10.00 | ★ $31.50 |
| AVG Volume (30 Days) | 66.3K | ★ 3.0M |
| Earning Date | 05-11-2026 | 04-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 67.39 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $58,435,000.00 | N/A |
| Revenue This Year | $10.06 | N/A |
| Revenue Next Year | $41.48 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 9.24 | N/A |
| 52 Week Low | $5.06 | $0.07 |
| 52 Week High | $13.74 | $20.58 |
| Indicator | LNSR | KALA |
|---|---|---|
| Relative Strength Index (RSI) | 45.25 | 76.31 |
| Support Level | $5.25 | $0.32 |
| Resistance Level | $6.39 | $20.58 |
| Average True Range (ATR) | 0.38 | 0.21 |
| MACD | 0.14 | 0.34 |
| Stochastic Oscillator | 48.95 | 74.23 |
LENSAR Inc is a commercial-stage medical device company focused on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts. The company Laser System incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, simplified procedure planning, efficient design, and precision. Its product portfolio consists of the LENSAR Laser System with Streamline IV and IntelliAxis and its associated consumable components. Geographically, the company generates the majority of its revenue from the United States, followed by Europe and Asia.
Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing therapies for rare and severe eye diseases. KALA'smain product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.